3.8 Article

High dose vitamin D administration in ventilated intensive care unit patients: A pilot double blind randomized controlled trial

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcte.2016.04.004

关键词

Vitamin D; Lung failure; Critical care; LL-37; Antimicrobial peptides

资金

  1. National Institutes of Health [NIH R21 HL110044, K24 DK096574, UL1 TR000454, T32 AA013528, T32 DK007298]

向作者/读者索取更多资源

Background: There is a high prevalence of vitamin D deficiency in the critically ill patient population. Several intensive care unit studies have demonstrated an association between vitamin D deficiency [25hydroxyvitamin D (25(OH) D) < 20 ng/mL] and increased hospital length of stay (LOS), readmission rate, sepsis and mortality. Material and Methods: Pilot, double blind randomized control trial conducted on mechanically ventilated adult ICU patients. Subjects were administered either placebo, 50,000 IU vitamin D-3 or 100,000 IU vitamin D-3 daily for 5 consecutive days enterally (total vitamin D-3 dose = 250,000 IU or 500,000 IU, respectively). The primary outcome was plasma 25(OH) D concentration 7 days after oral administration of study drug. Secondary outcomes were plasma levels of the antimicrobial peptide cathelicidin (LL37), hospital LOS, SOFA score, duration of mechanical ventilation, hospital mortality, mortality at 12 weeks, and hospital acquired infection. Results: A total of 31 subjects were enrolled with 13 (43%) being vitamin D deficient at entry (25(OH) D levels < 20 ng/mL). The 250,000 IU and 500,000 IU vitamin D-3 regimens each resulted in a significant increase in mean plasma 25(OH) D concentrations from baseline to day 7; values rose to 45.7 +/- 19.6 ng/mL and 55.2 +/- 14.4 ng/mL, respectively, compared to essentially no change in the placebo group (21 +/- 11.2 ng/mL), p < 0.001. There was a significant decrease in hospital length of stay over time in the 250,000 IU and the 500,000 IU vitamin D-3 group, compared to the placebo group (25 +/- 14 and 18 +/- 11 days compared to 36 +/- 19 days, respectively; p = 0.03). There was no statically significant change in plasma LL-37 concentrations or other clinical outcomes by group over time. Conclusions: In this pilot study, high-dose vitamin D-3 safely increased plasma 25(OH) D concentrations into the sufficient range and was associated with decreased hospital length of stay without altering other clinical outcomes. (C) 2016 The Author( s). Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据